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Abstract
Background: Emergence of multidrug-resistant Pseudomonas aeruginosa is of global concern. We aimed to identify
epidemiological relationships, the most common way of transmission, and risk factors for presence of Verona Integron-
encoded Metallo-β-lactamase (VIM)-positive P. aeruginosa (VIM-PA).
Methods: We conducted a network analysis and matched case-control studies (1:2:2). Controls were hospital-
based and matched with cases for ward, day of admission (control group 1 and 2) and time between
admission and the identification of VIM-PA (control group 1). The network was visualized using Cytoscape,
and risk factors were determined using conditional logistic regression.
Results: Between August 2003 and April 2015, 144 case patients and 576 control patients were recruited.
We identified 307 relationships in 114 out of these 144 patients, with most relationships (84.7%) identified at
the same department < 3 months after a previous case patient was discharged. In the multivariable model,
having undergone ≥1 gastroscopy (odds ratio [OR] = 4.40, 95% confidence interval [CI] = 2.00 to 9.65 and
OR = 2.47; 95% CI = 1.12 to 5.49), > 10 day use of selective digestive tract decontamination (SDD) (OR = 2.
97; 95% CI = 1.02 to 8.68 and OR = 4.61; 95% CI = 1.22 to 17.37), and use of quinolones (OR = 3.29; 95%
CI = 1.34 to 8.10 and OR = 3.95; 95% CI = 1.13 to 13.83 and OR = 4.47; 95% CI = 1.75 to 11.43) were
identified as risk factors when using both control groups.
Conclusions: The network analysis indicated that the majority of transmissions occurred on the wards, but
through unidentified and presumably persistent sources, which are most likely in the innate hospital environment.
Previous use of certain antibiotic regimens made patients prone to VIM-PA carriage. Additionally, gastroscopy could be
considered as a high-risk procedure in patients with risk factors. Our results add to the growing body of evidence that
infection control measures targeting VIM-PA should be focused on reducing antibiotics and eliminating sources in the
environment.
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Background
The emergence of multidrug-resistant strains of Pseudo-
monas aeruginosa (MDRPA) is of global concern [1, 2].
Infections with this resistant microorganism lead to in-
creased morbidity and mortality in patients; especially in
specific patient groups, such as those in intensive care
units [3–6]. MDRPA hospital outbreaks are mostly
caused by MDRPA which produce carbapenemases, with
as most clinically significant the metallo-β-lactamases
(MBL) [2]. Currently, the Verona Integron-encoded
MBL (VIM) is the most widespread MBL in P. aerugi-
nosa [2, 7–9]. Sources are often hard to eradicate be-
cause P. aeruginosa is known to form a biofilm in
environmental niches which protects it from cleaning
and disinfection actions [10, 11].
Since 2003, a VIM-positive clone of P. aeruginosa
(VIM-PA) has emerged in our hospital and became
entrenched causing multiple episodes of colonizations
and infections in patients [9, 12]. A systematic review
published by our research group showed that the leading
risk factors for acquiring MDRPA were carbapenem use
and having medical devices [13]. However, risk factors
are likely to be outbreak specific because of different
local circumstances and patient populations.
The aim of this study was first to identify epidemio-
logical relationships between patients with a VIM-PA,
and to identify the most common way of transmission.
Second, we aimed to identify risk factors for presence of
VIM-PA among colonized and/or infected patients with
a case-control study. When a case-control study is used
to understand an outbreak, it is often not clear what the
best control group is. Both under- and overmatching
may affect the results; in essence, the choice of the con-
trol determines the outcome. Therefore, our third aim
was identifying the most appropriate control group.
Methods
Ethics statement
Written approval to conduct this study was received
from the medical ethics research committee of the
Erasmus MC University Medical Centre (Erasmus MC),
Rotterdam, the Netherlands (MEC-2015-240). This study
is registered in the Dutch National Trial Register
(NTR5145).
Setting
This retrospective study was conducted at the Erasmus
MC in Rotterdam, the Netherlands, using data from
August 2003 until April 2015. In this 1200-bed univer-
sity hospital all medical specialties are available; orga-
nized into 48 departments. The Department of Adult
Intensive Care (adult ICU) comprises of three high-level
ICU wards, and each ward has only single-patient
rooms. At the ICU, patients expected to be on a
mechanical ventilator for > 48 h or anticipated to be ad-
mitted to the ICU for > 72 h receive selective digestive
tract decontamination (SDD). The SDD regimen is iden-
tical to the regimen used by de Smet et al., including 4
days of cefotaxime intravenously [14]. The total number
of clinical admissions and clinical admission days from
2003 until 2015 are available in Additional file 1.
Patient inclusion and microbiological analysis
Patients were included if identified with VIM-PA be-
tween 48 h after admittance to and 48 h after discharge
from a department in the main Erasmus MC building.
Patients were excluded if admitted only to the Erasmus
MC Sophia Children’s Hospital or only to the Erasmus
MC Cancer Institute. These buildings are physically sep-
arated from the main building, and have their own em-
ployees. To our knowledge, there has been no cross-over
of VIM-PA to and from these separate buildings. In
addition, 22 patients that were involved in an outbreak
resulting from a contaminated duodenoscope used for
endoscopic retrograde cholangiopancreatography were
excluded. The exact cause, source and transmission
route were known and it was therefore investigated and
reported separately [15].
Cultures taken for clinical diagnostic purposes were
processed in the laboratory using standard microbio-
logical methods. In case of suspected growth of
carbapenemase-producing P. aeruginosa or MDRPA, an
in-house polymerase chain reaction (PCR) for detection
of blaVIM on LightCycler 480 (Roche Diagnostics, Al-
mere, The Netherlands) was performed using previously
reported primers [9, 12]. For screening for VIM-PA,
swabs were obtained from throat and rectum, cultured
overnight at 35 °C in a Tryptic Soy Broth with ceftazi-
dime (2 mg/L) and vancomycin (50 mg/L), followed by
our in-house PCR test on the broth. Positive PCR results
were confirmed by subculturing the broth on a blood
agar (BD Diagnostics, Breda, The Netherlands); P. aeru-
ginosa growing on this agar plate was subjected to bla-
VIM PCR. Identification and susceptibility testing was
performed using Vitek2 (bioMérieux, Marcy l’Etoile,
France). Since January 2013, the MALDI-TOF (Bruker
Daltonics, Bremen, Germany) was used for identifica-
tion. Clonal relatedness of VIM-PA from clinical and
screening cultures was determined using the DiversiLab
system with the Pseudomonas kit (bioMérieux).
General infection prevention and control measures
were installed after each case was identified (e.g. isola-
tion). However, in 2011 these measures were intensified;
at two adult intensive care units (ICUs), twice-weekly
screening for VIM-PA (i.e. rectum and throat cultures)
was implemented from October 2011. However, after
April 2014, this was reduced to once a week. After
August 2014, the weekly screening halted; however, was
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re-implemented in September 2014 because a new case
of VIM-PA was identified from a clinical sample. Add-
itionally, at the ICU rectum and throat cultures on VIM
are taken upon admittance and discharge of patients. At
the neurological high care ward, screening took place
once a week from August 2013 until January 2016.
Network analysis
Admission histories in time and department/room loca-
tion of patients identified with VIM-PA were retrieved to
define epidemiological relatedness. Each identified rela-
tion was classified in one out of four categories (Table 1).
Then, the data were imported into Cytoscape v3.2.1
(http://www.cytoscape.org) and the network was visual-
ized [16]. It was analysed whether a patient only ‘re-
ceived’, only ‘transmitted’, or ‘received and transmitted’
the VIM-PA following the definitions in Table 1. “Only
received” indicated that a patient did not have epidemio-
logical links to patients identified with a VIM-PA at a
later time, “only transmitted” indicated that a patient did
not have epidemiological links to patients identified with
a VIM-PA earlier in time. “Received and transmitted” in-
dicated that a patient had epidemiological relationships
to patients identified with VIM-PA earlier in time and
later in time.
Case-control studies
The risk factor analysis was performed in individual
matched retrospective case-control studies, using a 1:2:2
ratio, with hospital-based controls. All information was
extracted from the electronic medical records. A list of
all patient and treatment related variables collected for
cases and controls is presented in Additional file 2.
Control groups
Patients in control group 1 and 2 were matched for the
following three characteristics: I: admitted to the same
ward where the case supposedly acquired the VIM-PA
(i.e. the ward where the patient was admitted 48 h be-
fore the positive culture) (exact match), II: being admit-
ted on the same date as the case (best match), III:
having the same days of exposure as the case (i.e. the
days between admittance and the date of the first
positive culture with VIM-PA) (best match). If exact
matching was not possible ─with the exception of
ward─ exposure time was found to be the most impera-
tive factor. Patients in control group 3 and 4 were
matched for the following characteristics: I: admitted to
the same ward as the case (exact match), II: admittance
on the same date as the case (best match). The control
patient had to be free of colonization or infection with
VIM-PA. This could be proven either by negative
screening cultures or by the absence of clinical cultures
with VIM-PA. A control patient could not serve as a
control more than two times; within and between the
four different control groups. Also, a case patient could
never be selected as a control patient.
Statistical analyses
For continuous variables, means or medians were calcu-
lated. For categorical variables, percentages were calcu-
lated. The conditional logistic regression model was
used in both univariate and multivariable analyses. Uni-
variate analyses were conducted using the COXREG
procedure in SPSS version 21 (IBM Corp., Armonk,
New York, USA). Characteristics with a P-value of < 0.1
in univariate analysis were included in the multivariable
analyses. Treatment variables could be included as 1)
use yes/no, 2) use for 0/1–3/≥4 days or 3) use for 0/1-3/
4-10/≥11 days. Selection for inclusion in the multivari-
able model of either category 1, 2 or 3 of a certain anti-
biotic was based on: 1) > 5 patients in present in each
group, 2) estimates of the different categories had to
show a difference of at least 1 odds ratio (OR). Multivar-
iable analyses were conducted using conditional logistic
regression with dynamic ridge penalties in the R Project
for statistical computing version 3.3.1 (Vienna, Austria).
Subgroup analyses were performed for ward of acquisi-
tion of case patients and matched controls being ICU or
being non-ICU, as well as for case patients in clonal
clusters as indicated by the typing results. Additionally,
analyses were performed between patients in control
group 1&2 and 3&4. Results were presented as ORs with
95% confidence intervals (CI). P-values < 0.05 were con-
sidered statistically significant. Graphs were created
using GraphPad Prism Version 7.01 (GraphPad
Software, Inc. CA, USA).
Results
Included patients
Out of 166 patients identified with a VIM-PA between
August 2003 and April 2015, eight children were ex-
cluded because they were admitted only to the Erasmus
MC Sophia Children’s hospital and one patient was ex-
cluded because admitted only to the Erasmus MC Can-
cer Institute. In addition, 13 patients were excluded
because the VIM-PA was identified within 48 h after
Table 1 Definitions of epidemiological relatedness
Definite1 Probable Possible-
I
Possible-
II
Impossible
Same patient
room
1 1 0 0 0
Same
department
1 1 1 1 0
Same period 1 0a 1 0a 0a/0/1
0 = no; 1 = yes, 0a = < 3 months after previous positive patient was
discharged. 1Definition definite was not possible at the intensive care units
because only single patient rooms are present
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admission. Ultimately, 144 patients were included in the
network analysis and as case patients in the case-control
study (Additional file 1). Nineteen different wards of ac-
quisition were identified, including three ICUs (i.e. two
general adult ICUs and 1 thoracic ICU). The top five lo-
cations of acquisition were the two general adult ICUs
(87 patients, 60.4%), the gastro-intestinal surgical ward
(10 patients; 6.9%), and the gastroenterology and hepa-
tology ward (7 patients, 4.9%). Typing showed that the
VIM-PA of 29 (20.1%) patients belonged to clonal clus-
ter A, 105 (72.9%) to clonal cluster B, 7 (4.9%) did not
belong to clonal cluster A or B, and it was not possible
to type strains from three patients (2.1%).
Network analysis
From 2003 until 2015, we identified 307 relationships in
114 out of 144 patients (Table 1, Fig. 1). Thirty out of
144 patients did not have relationships to other case
patients (20.8%). When considering the definitions
(Table 1) we identified nine probable relationships, 38
possible-I relationships and 260 possible-II relationships
at 12 different departments. Most relationships (92%)
were identified at the ICU. Twenty-five patients (17.4%)
only ‘received’ the VIM-PA, 22 (15.3%) only ‘transmitted’
VIM-PA and 67 (46.5%) ‘received and transmitted’ VIM-
PA.
Case-control studies
Matching
It was impossible to perfectly match all cases to four
controls. Overall, perfect matching was achieved in
38.2% (range: 16.0%–66.0%). For cases, the median days
from admission to acquisition of VIM-PA was 14 days
(range: 1–114 days). In the control groups, the median
error in days was 4, 4, − 1 and − 1 days respectively.
Seventeen patients served two times as control patient
between the four control groups (11.8%).
Risk factors for acquisition
Patient related clinical variables with crude odds ratios,
95% CI and P-values are presented in Table 2. Compared
to control group 1&2 and control group 3&4, the me-
dian length of admission was significantly longer and the
1-year mortality rate was significantly higher in case pa-
tients (Table 2). Treatment related variables with crude
odds ratios, 95% CI and P-values are presented in Table 3
and in Additional file 3. When comparing cases to con-
trol group 1&2, multivariable analysis revealed five risk
factors; two patient related clinical risk factors, and three
treatment related risk factors (Fig. 2). The highest odds
ratio was identified for having undergone ≥1 gastroscopy
6 months prior to the identification of VIM-PA
(OR = 4.40, 95%CI = 2.00 to 9.65, P < 0.001). When
comparing cases to control group 3&4, one patient re-
lated clinical protective factor was identified (i.e. malig-
nancies) and one risk factor (i.e. gastroscopy) (Fig. 2).
Also, four treatment related risk factors were identified;
use of piperacillin/tazobactam, 1–3 day and > 3 day use
of quinolones and > 10 day use of SDD (Fig. 2). The
highest odds ratio was identified for > 10 day use of
SDD (OR = 4.61, 95%CI = 1.22 to 17.37, P = 0.024). In
both case-control studies, previous use of quinolones,
use of SDD for > 10 days, and having undergone ≥1 gas-
troscopy 6 months prior to the identification of VIM-PA
were identified as risk factors, and could therefore be
considered robust risk factors.
Fig. 1 Network of 307 relationships in 114 out of 144 patients identified with VIM-PA. Thirty out of 144 patients did not have relationships to
other case patients (20.8%). Edge colours represent different Erasmus MC departments; green represents the two adult ICU wards. Line shapes
represent the different epidemiological relationships as described in Table 1: contiguous line = probable, dash line = possible A, solid line =
possible B. The arrow shows the direction of the relationship
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Table 2 Patient related clinical variables, univariate analyses between cases and controls 1&2 and between cases and controls 3&4
Variables Cases
(n = 144)
Controls 1&2
(n = 288)
Crude OR
(95% CI)
P-value Controls 3&4
(n = 288)
Crude OR
(95% CI)
P-value
Basic characteristics
Age, years, median (range) 58.3 (17–
82)
60.3 (17–92) 0.998
(0.986–0.1010)
0.723 61.1 (17–91) 0.995
(0.982–1.007)
0.407
Male gender (%) 83 (57.6) 174 (60.4) 0.886
(0.584–1.345)
0.570 167 (58.0) 0.985
(0.650–1.493)
0.944
28-day mortality (%) 41 (28.5) 69 (24.0) 1.283
(0.804–2.048)
0.296 40 (13.9) 2.677
(1.577–4.544)
<
0.001
1-year mortality (%) 82 (56.9) 95 (33.0) 2.680
(1.754–4.094)
<
0.001
63 (21.9) 4.950
(3.072–7.976)
<
0.001
Transferred from another hospital (%) 50 (34.7) 60 (20.8) 2.000
(1.279–3.128)
0.002 50 (17.4) 2.405
(1.530–3.782)
<
0.001
Median length of admission (range) 55 (3–338) 25 (1–258) 1.021
(1.014–1.028)
<
0.001
12 (1–1102) 1.021
(1.014–1.027)
<
0.001
Erasmus MC 1y before VIM-PA (%) 64 (44.4) 111 (38.5) 1.278
(0.851–1.920)
0.237 109 (37.8) 1.348
(0.881–2.064)
0.169
Erasmus MC ICU 1y before VIM-PA (%) 14 (9.7) 15 (5.2) 1.867
(0.901–3.867)
0.093 14 (4.9) 2.131
(0.976–4.652)
0.058
Surgery (%) 87 (60.4) 119 (41.3) 2.165
(1.432–3.275)
<
0.001
121 (42.0) 2.119
(1.399–3.209)
<
0.001
Underlying diseases
Cystic fibrosis (%) 2a (1.4) 3 (1.0) NA NA 2 (0.7) NA NA
Chronic respiratory illness (%) 29 (20.1) 43 (14.9) 1.488
(0.861–2.571)
0.155 43 (14.9) 1.518
(0.868–2.655)
0.144
Chronic kidney failure (%) 5 (3.5) 3 (1.0) 3.33
(0.797–13.948)
0.099 11 (3.8) 0.903
(0.304–2.689)
0.855
Acute kidney failure; use of CVVH (%) 28 (19.4) 18 (6.3) 3.471
(1.844–6.533)
<
0.001
10 (3.5) 6.651
(3.022–14.638)
<
0.001
Chronic liver failure (%) 5 (3.5) 7 (2.4) 1.480
(0.442–4.952)
0.525 17 (5.9) 0.588
(0.217–1.594)
0.297
Acute liver failure (%) 0 (0) 6 (2.1) NA NA 3 (1.0) NA NA
Chronic problems of the gastrointestinal tract
(%)
19 (13.2) 28 (9.7) 1.377
(0.758–2.502)
0.294 26 (9.0) 1.603
(0.822–3.126)
0.166
Acute problems of the gastrointestinal tract (%) 28 (19.4) 39 (13.5) 1.493
(0.894–2.494)
0.126 54 (18.8) 1.047
(0.627–1.750)
0.861
Auto-immune disease (%) 7 (4.9) 18 (6.3) 0.762
(0.308–1.886)
0.556 26 (9.0) 0.520
(0.221–1.223)
0.134
Human immunodeficiency virus (%) 0 (0) 2 (0.7) NA NA 4 (1.4) NA NA
Diabetes (%) 24 (16.7) 37 (12.8) 1.353
(0.776–2.360)
0.287 48 (16.7) 1.000
(0.579–1.726)
1.000
Solid organ transplant recipient (%) 20a (14.0) 20 (6.9) 2.257
(1.139–4.473)
0.020 30 (10.4) 1.463
(0.784–2.729)
0.232
Stem cell/bone marrow transplant recipient (%) 7a (4.9) 6 (2.1) 3.562
(0.875–14.493)
0.076 1 (0.3) NA NA
Use of immunosuppressive agents (%) 55 (38.2) 71 (24.7) 1.920
(1.236–2.985)
0.004 55 (19.1) 2.493
(1.602–3.879)
<
0.001
Malignancies (%) 32 (22.2) 76 (26.4) 0.777 (0.472–
1.280)
0.322 92 (31.9) 0.570
(0.347–0.936)
0.026
Neutropenia, < 500 cells/μL (%) 3b (2.7) 4b (2.1) 0.883
(0.159–4.889)b
0.886 7b (2.4) 0.667
(0.164–2.713)b
0.571
Endoscopies
Colonoscopy (%) 7 (4.9) 10 (3.5) 1.400
(0.533–3.678)
0.495 12 (4.2) 1.202
(0.432–3.345)
0.724
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Univariate results of the subgroup analyses are pre-
sented in Additional files 4 and 5. Multivariable results
are displayed in Fig. 3. There are differences in identified
risk factors in the different subgroups. For example, for
patients with DiversiLab type A endoscopies did not
seem to play a role, whereas in type B they did. Also, at
the ICU antibiotic use (trimethoprim/sulfamethoxazole)
was identified as a risk factor in combination with hav-
ing undergone ≥1 gastroscopy and bronchoscopy
6 months prior to the identification of VIM-PA, whereas
at non-ICU wards it was a combination of having under-
gone ≥1 gastroscopy 6 months prior to the identification
of VIM-PA and surgery or being admitted at the
Erasmus MC before.
Univariate differences between control group 1&2 and
3&4 are presented in Additional file 6. Multivariable
analysis revealed only two differences between the con-
trol groups, regarding protection by acute gastrointes-
tinal tract problems and use of nitrofurantoin (Fig. 2).
Discussion
Our study aimed to identify epidemiological relation-
ships, the most common way of transmission and risk
factors for presence of VIM-PA. In the network analysis,
we did not identify definite relationship and only nine
probable relationships. Therefore, the same patient
room, either sharing a patient room or being admitted at
the same patient room within 3 months, is not the most
likely source. However, there was a relation with the
same department. Surprisingly, the same admission
period seems not to be important; most relationships
were identified within 3 months after the previous posi-
tive patient was discharged. Thus, the majority of trans-
missions occurred on the wards in a wide time frame.
Therefore, it must have occurred through unidentified
sources, which may be either undetected patients or un-
identified sources in the innate environment. Given the
fact that patients at the ICUs and neurology high-care
ward were frequently screened; we assume that un-
detected patients are not plausible. Our hypothesis is
that persistent sources in the innate environment play
an important role in the route of transmission of this
pathogen. This is in agreement with current knowledge
on the behaviour of this bacterium, as well as previous
outbreak reports that identified the environment as
source/reservoir [13, 17].
The case-control studies showed first that previous
use of certain antibiotics were associated with an in-
creased risk of acquisition of VIM-PA; especially the use
of quinolones, piperacillin/tazobactam, and trimetho-
prim/sulfamethoxazole should be avoided if possible.
Second, gastroscopy and bronchoscopy were identified
Table 2 Patient related clinical variables, univariate analyses between cases and controls 1&2 and between cases and controls 3&4
(Continued)
Variables Cases
(n = 144)
Controls 1&2
(n = 288)
Crude OR
(95% CI)
P-value Controls 3&4
(n = 288)
Crude OR
(95% CI)
P-value
Sigmoidoscopy (%) 7 (4.9) 5 (1.7) 2.800
(0.889–8.822)
0.079 8 (2.8) 1.750
(0.635–4.826)
0.280
Endoscopic ultrasound (%) 7 (4.9) 26 (9.0) 0.490
(0.202–1.189)
0.115 19 (6.6) 0.684
(0.260–1.802)
0.443
Gastroscopy (%) 75 (52.1) 50 (17.4) 6.609
(3.803–11.485)
<
0.001
59 (20.5) 4.529
(2.79–7.335)
<
0.001
ERCP (%) 17 (11.8) 15 (5.2) 2.520
(1.190–5.336)
0.016 10 (3.5) 3.917
(1.678–9.143)
0.002
Bronchoscopy (%) 41 (28.5) 34 (11.8) 3.159
(1.841–5.422)
<
0.001
33 (11.5) 3.030
(1.800–5.103)
<
0.001
Transoesophageal Echocardiography (TEE) (%) 12 (8.3) 13 (4.5) 1.846
(0.842–4.046)
0.126 13 (4.5) 1.901
(0.849–4.257)
0.118
Medical devices
Mechanical ventilation (%) 129 (89.6) 210 (72.9) 4.921
(2.284–10.600)
<
0.001
185 (64.2) 8.211
(3.857–17.481)
<
0.001
Tracheostomy (%) 29 (20.1) 38 (13.2) 1.801
(1.011–3.211)
0.046 9 (3.1) 7.883
(3.443–18.045)
<
0.001
Extracorporeal membrane oxygenation (%) 2 (1.4) 0 (0) NA NA 0 (0) NA NA
Central venous catheter (%) 103 (71.5) 124 (43.1) 4.121
(2.477–6.854)
<
0.001
77 (26.7) 9.040
(5.101–16.023)
<
0.001
Abbreviations: VIM-PA Verona Integron-encoded Metallo-β-lactamase (VIM)-positive Pseudomonas aeruginosa, 95% CI 95% confidence interval, y year, ICU intensive
care unit, CVVH Continuous Veno-Venous Hemofiltration, ERCP Endoscopic Retrograde Cholangiopancreatography
a1 case missing because no medical background was available
bFor 32 cases, 99 controls 1&2 and 108 controls 3&4 no information about neutrophils was available
bold = statistically significant
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as risk factors (Fig. 2). Third, the results of the two dif-
ferent case-control studies were largely in line with each
other, with three common risk factors (i.e. previous use
of quinolones, use of SDD for > 10 days, and having
undergone ≥1 gastroscopy 6 months prior to the identi-
fication of VIM-PA) that could therefore be considered
as robust. The assumption would be that certain antibi-
otics change the normal gut or throat flora in such a
way that multidrug-resistant bacteria more easily attach
to and colonize either the gut or throat. Nevertheless,
multidrug-resistant microorganisms have to be offered
to the patient, and this may occur through endoscopic
procedures by contaminated endoscopes or using water
from a contaminated source. Both the previous use of
antibiotics and prior procedures with flexible endoscopes
have been highlighted in previous studies as risk factors
for acquisition of various multidrug microorganisms, in-
cluding VIM-PA [18, 19].
The group of antibiotics that favours presence of VIM-
PA (i.e. increases a patients’ susceptibility to acquire
VIM-PA) depends on the choice of the control group.
Furthermore, we learned that although highly significant
factors were obtained with one group of controls, these
can disappear when other groups are compared as these
groups differ in inclusion criteria or definition; the re-
sults highly depend on the choice of the control.
Limitations
Network analysis
Criteria for epidemiological relationships, especially rela-
tionships in time and space, are not clearly defined for
outbreaks with multidrug-resistant bacteria. We
Table 3 Treatment related variables, univariate analyses between cases and controls 1&2 and between cases and controls 3&4
Variablesc Cases
(n = 138a)
Controls 1&2
(n = 288)
Crude OR
(95% CI)
P-value Controls 3&4
(n = 288)
Crude OR
(95% CI)
P-value
Antifungals (%) 82 (59.4) 79 (28.0)b 4.863
(2.886–8.194)
< 0.001 50 (17.7)b 5.890
(3.647–9.512)
< 0.001
Antivirals (%) 16 (11.6) 19 (6.7)b 1.913
(0.899–4.071)
0.092 17 (6.0)b 2.053
(1.011–4.169)
0.047
Aminoglycosides (%) 51 (37.0) 53 (18.8) 2.988
(1.769–5.046)
< 0.001 24 (8.5) 6.832
(3.692–12.643)
< 0.001
Amoxicillin/clavulanic acid (%) 39 (29.1) 48 (17.0)b 2.014
(1.196–3.394)
0.009 40 (14.2)b 2.388
(1.428–3.992)
0.001
Carbapenems (%) 58 (42.0) 58 (20.7) 3.124
(1.898–5.142)
< 0.001 26 (9.2) 6.762
(3.810–12.000)
< 0.001
Cephalosporins (%) 104 (77.6) 131 (46.5) 3.942
(2.383–6.520)
< 0.001 107 (37.9) 6.407
(3.692–11-121)
< 0.001
Colistin (%) 17 (12.7) 20 (7.1)b 1.896
(0.926–3.880)
0.080 12 (4.3)b 4.282
(1.756–10.437)
0.001
Macrolides (%) 60 (44.8) 64 (22.7) 2.702
(1.696–4.304)
< 0.001 27 (9.6) 6.881
(3.885–12.190)
< 0.001
Metronidazole (%) 48 (35.8) 48 (17.0) 2.445
(1.534–3.898)
< 0.001 32 (11.3)b 4.689
(2.630–8.360)
< 0.001
Nitrofurantoin (%) 17 (12.7) 12 (4.3)b 3.486
(1.543–7.878)
0.003 24 (8.5) 1.527
(0.767–3.039)
0.228
Penicillin (%) 29 (21.6) 49 (17.4) 1.226
(0.739–2.032)
0.431 31 (11.0) 2.100
(1.199–3.678)
0.009
Piperacillin/tazobactam (%) 49 (36.6) 50 (17.7)b 2.774
(1.666–4.621)
< 0.001 32 (11.3)b 4.572
(2.604–8.025)
< 0.001
Quinolones (%) 94 (70.1) 88 (31.2) 6.087
(3.553–10.429)
< 0.001 53 (18.8) 9.193 (5.284–15.996) < 0.001
Trimethoprim/sulfamethoxazole (%) 32 (23.9) 23 (8.2)b 3.606
(1.930–6.740)
< 0.001 19 (6.7)b 3.834
(2.098–7.007)
< 0.001
Vancomycin (%) 74 (55.2) 51 (18.1) 6.355
(3.652–11.057)
< 0.001 27 (9.6) 9.847
(5.437–17.836)
< 0.001
Other antibiotics (%) 32 (23.9) 28 (9.9)b 3.074
(1.680–5.627)
< 0.001 30 (10.6)b 2.684
(1.512–4.763)
0.001
Selective digestive tract decontamination (%) 92 (68.7) 109 (38.7) 4.583
(2.641–7.952)
< 0.001 59 (20.9) 10.864
(5.748–20.536)
< 0.001
Abbreviations: 95% CI 95% confidence interval, aData on antibiotics of the first six cases was missing, bold = statistically significant, P-value < 0.05. bIncluded in
multivariable analysis. cFor categorical data see Additional file 3
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developed criteria which are easy to apply; however, in-
herent to this is a simplification of the truth. We
propose that these definitions would be modified or
extended in case data from future studies warrants.
Case-control studies
First, this is a single-centre case-control study, which
possibly hampers generalizability. Second, matching on
ward of acquisition and length of stay prior to the posi-
tive culture might have caused additional matching on
e.g. comorbidities and disease severity. However, we
have done this deliberately. When comparing ICU to
non-ICU patients, disease severity and possibly also
comorbidities will be risk factors just because the
groups are not similar. Third, misclassification of
exposure could be present; not all control patients were
cultured for VIM-PA, which could lead to VIM-PA car-
riers present in control group. However, this misclassi-
fication if present could only have led to an
underestimation of the identified effects. Fourth, per-
fect matching was only achieved in 38%. This seems
low; however, 100% perfect matching is not possible for
large case-control studies including patients who have
complicated medical histories and futures. Possibly, the
percentage of perfect matching could be added as an
item to the STROBE statement [20].
In one of the subgroup analyses, differences were iden-
tified between DiversiLab clonal cluster A and B (Fig. 3).
Fig. 3 Risk factors identified using multivariable analysis of subgroups DiversiLab type A or type B and ward of acquisition of the case patient
being the intensive care unit (ICU) or non-ICU wards. Abbreviations: SDD = selective digestive tract decontamination, 95%CI = 95% confidence
interval, ICU = intensive care unit
Fig. 2 Risk factors and protective factors identified using multivariable analysis. Abbreviations: SDD = selective digestive tract decontamination,
95%CI = 95% confidence interval
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However, although widely applied, the DiversiLab system
can be considered a limitation of the study, since avail-
able data regarding the DiversiLab system for P. aerugi-
nosa are contradictory. A review by Brossier et al. on the
performance of the DiversiLab system for P. aeruginosa
concluded that the results should be interpreted with
caution, and always in combination with epidemiological
data, as was done in our study [21].
Conclusion
The network analysis indicated that the majority of
transmissions occurred on the wards, but through un-
identified and presumably persistent sources, which
are most likely in the innate hospital environment.
Previous use of certain antibiotic regimens made pa-
tients prone to VIM-PA carriage. Additionally, gas-
troscopy could be considered as a high-risk procedure
in patients with risk factors.
Recommendation
If there is an outbreak with VIM-PA, we showed that
first; the entire ward should be seen as reservoir and
as contaminated. Therefore, cleaning and disinfection
practices should be installed and possible sources
should be eliminated. We also feel that it is especially
important to search for unknown reservoirs in the
environment. Second, use of particularly quinolones
should be avoided because this could make a patient
‘prone’ for acquiring VIM-PA. Third, we showed that
in an outbreak setting gastroscopy and bronchoscopy
could be seen as high-risk procedures. Finally, a case-
control study should be executed to identify outbreak
specific risk factors. Because we showed that if you
change matching criteria outcomes do differ, it would
be advisable to always include multiple definitions for
control inclusion.
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